TMOQ3 20261/5Estimate vs Actual
Earnings per Share
- Estimate
- $6.47
- Actual
- $6.68
+3.3% vs Estimate
Revenue
- Estimate
- $12.1 B
- Actual
- $12.1 B
+0.6% vs Estimate
Thermo Fisher Scientific Q3 2026 · Story
Read the quarter card by card, ready to share.
TMOQ3 20261/5TMOQ3 20262/5Guidance
Full-Year Revenue
- Company Guidance
- 47.7 – 48.2 billion
- Market Estimate
- 47.87 billion
Revised Up 0.4% ▲
Full-Year Adjusted EPS
- Company Guidance
- 25.13 – 25.43 $
- Market Estimate
- 25.13 $
Revised Up 0.6% ▲
Full-Year Organic Growth
- Company Guidance
- 4%
TMOQ3 20263/5Price Reaction
First Full Session
+ 1.0%
From the prior close to the report-day close.
TMOQ3 20264/5In 30 Seconds
Revenue of $12.14 billion beat estimates by 1.6%, and adjusted EPS of $6.68 beat by 4.4%.
- Organic growth accelerated to 6%; full-year revenue and EPS guidance were revised up.
- The stock fell before the open, then neared its 52-week high and closed up 1.0%.
First point of the analysis's “In 30 Seconds”.
Full AnalysisTMOQ3 20265/5Score
62/ 100
ViewHOLD
Not Investment Advice